Seelos Therapeutics SEEL shares are trading higher on Thursday after the company announced the initiation of a preclinical study of SLS-004 In Parkinson's Disease.
Seelos Therapeutics is engaged in the pharmaceutical industry. The company's pipeline products include SLS-002 which is intranasal racemic ketamine for patients with suicidality in post-traumatic stress disorder and depressive disorder; SLS-006 which is a small molecule, partial dopamine agonist for Parkinson's Disease; and SLS-005 is Trehalose, a protein stabilizer.
Seelos Therapeutics shares were trading up 5.88% at $1.26 at time of publication on Thursday. The stock has a 52-week high of $2.87 and a 52-week low of 42 cents.
Related Link:
Seelos Therapeutics Shares Rally Following Deal For Gene Therapy Program
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
